SUMMARY HIV-1 DNA persists in infected cells despite combined antiretroviral therapy
(cART), forming viral reservoirs. Recent trials of strategies targeting latent HIV reservoirs …

Candidate enhancers can be identified on the basis of chromatin modifications, the binding
of chromatin modifiers and transcription factors and cofactors, or chromatin accessibility …

Eradicating HIV-1 in infected individuals will not be possible without addressing the
persistence of the virus in its multiple reservoirs. In this context, the molecular …

Several recent studies indicate that mutations in the human immunodeficiency virus type 1
(HIV-1) 3′ polypurine tract (3′ PPT) motif can reduce sensitivity to the integrase inhibitor …

Reverse transcription of viral RNA and the subsequent integration of reverse transcripts are
the classical early events of the HIV-1 life-cycle. Simultaneously, abundant unintegrated …

Integrase strand-transfer inhibitors (INSTIs), such as raltegravir (RAL), elvitegravir, or
dolutegravir (DTG), are efficient antiretroviral agents used in HIV treatment in order to inhibit …

Human immunodeficiency virus (HIV) normally escapes from antiviral drugs by selecting
mutations in the targeted gene. The integrase strand-transfer inhibitor (INSTI) dolutegravir …

ABSTRACT HIV-1 cDNA pre-integration complexes persist for weeks in macrophages and
remain transcriptionally active. While previous work has focused on the transcription of HIV …

Le cycle de vie du VIH-1 requiert le processus de transcription inverse. Ce processus
permet la synthèse d'un ADN double-brin à partir du génome viral constitué de deux copies …

Candidate enhancers can be identified on the basis of chromatin modifications, the binding
of chromatin modifiers and transcription factors and cofactors, or chromatin accessibility …